Immunosuppressant Drug Labels Updated To Reflect Infection Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requires the labels for a handful of immunosuppressants used in kidney transplantation to reflect risk of infection, including activation of latent viral infections.
You may also be interested in...
Increased Mortality In Rapamune Liver Transplant Study Sparks FDA Alert
Wyeth notified the agency about increased mortality in the sirolimus arm of a comparative study and is seeking a safety update for the immunosuppressant’s labeling, the company said.
CellCept, Myfortic Labeling Get PML Warning
Labeling update for transplant drugs follows postmarketing reports of progressive multifocal leukoencephalopathy.
IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.